Anandamide and vanilloid TRPV1 receptors

Ruth Alexandra Ross

Research output: Contribution to journalArticle

387 Citations (Scopus)

Abstract

A large body of evidence now exists to substantiate that the endocannabinoid, anandamide, activates TRPV1 receptors. It is a low intrinsic efficacy TRPV1 agonist that behaves as a partial agonist in tissues with a low receptor reserve, while in tissues with high receptor reserve and in circumstances associated with certain disease states, it behaves as a full agonist. The efficacy of anandamide as a TRPV1 agonist is influenced by a succession of factors including receptor reserve, phosphorylation, metabolism and uptake, CB1 receptor activation, voltage, temperature, pH and bovine serum albumin. There are indications that the endocannabinoid system may play a role in the modulation of TRPV1 receptor activation. The activation of TRPV1 receptors by anandamide has potential implications in the treatment of inflammatory, respiratory and cardiovascular disorders. The relative importance of anandamide as a physiological and/or pathophysiological TRPV1 receptor agonist in comparison to other potential candidates has yet to be revealed.

Original languageEnglish
Pages (from-to)790-801
Number of pages11
JournalBritish Journal of Pharmacology
Volume140
Issue number5
DOIs
Publication statusPublished - Nov 2003

Keywords

  • anandamide
  • vanilloid
  • TRPV1
  • cannabinoid
  • endocannabinoid
  • endovanilloid
  • lipoxygenase
  • PROTEIN-KINASE-C
  • ACID AMIDE HYDROLASE
  • CANNABINOID CB1 RECEPTOR
  • PRIMARY SENSORY NEURONS
  • NERVE GROWTH-FACTOR
  • ROOT GANGLION NEURONS
  • RAT SPINAL-CORD
  • VR1 RECEPTORS
  • PHARMACOLOGICAL CHARACTERIZATION
  • FACILITATED TRANSPORT

Cite this

Anandamide and vanilloid TRPV1 receptors. / Ross, Ruth Alexandra.

In: British Journal of Pharmacology, Vol. 140, No. 5, 11.2003, p. 790-801.

Research output: Contribution to journalArticle

Ross, Ruth Alexandra. / Anandamide and vanilloid TRPV1 receptors. In: British Journal of Pharmacology. 2003 ; Vol. 140, No. 5. pp. 790-801.
@article{83708411ca6e4d2fa88d3b1e0e50ceba,
title = "Anandamide and vanilloid TRPV1 receptors",
abstract = "A large body of evidence now exists to substantiate that the endocannabinoid, anandamide, activates TRPV1 receptors. It is a low intrinsic efficacy TRPV1 agonist that behaves as a partial agonist in tissues with a low receptor reserve, while in tissues with high receptor reserve and in circumstances associated with certain disease states, it behaves as a full agonist. The efficacy of anandamide as a TRPV1 agonist is influenced by a succession of factors including receptor reserve, phosphorylation, metabolism and uptake, CB1 receptor activation, voltage, temperature, pH and bovine serum albumin. There are indications that the endocannabinoid system may play a role in the modulation of TRPV1 receptor activation. The activation of TRPV1 receptors by anandamide has potential implications in the treatment of inflammatory, respiratory and cardiovascular disorders. The relative importance of anandamide as a physiological and/or pathophysiological TRPV1 receptor agonist in comparison to other potential candidates has yet to be revealed.",
keywords = "anandamide, vanilloid, TRPV1, cannabinoid, endocannabinoid, endovanilloid, lipoxygenase, PROTEIN-KINASE-C, ACID AMIDE HYDROLASE, CANNABINOID CB1 RECEPTOR, PRIMARY SENSORY NEURONS, NERVE GROWTH-FACTOR, ROOT GANGLION NEURONS, RAT SPINAL-CORD, VR1 RECEPTORS, PHARMACOLOGICAL CHARACTERIZATION, FACILITATED TRANSPORT",
author = "Ross, {Ruth Alexandra}",
year = "2003",
month = "11",
doi = "10.1038/sj.bjp.0705467",
language = "English",
volume = "140",
pages = "790--801",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Anandamide and vanilloid TRPV1 receptors

AU - Ross, Ruth Alexandra

PY - 2003/11

Y1 - 2003/11

N2 - A large body of evidence now exists to substantiate that the endocannabinoid, anandamide, activates TRPV1 receptors. It is a low intrinsic efficacy TRPV1 agonist that behaves as a partial agonist in tissues with a low receptor reserve, while in tissues with high receptor reserve and in circumstances associated with certain disease states, it behaves as a full agonist. The efficacy of anandamide as a TRPV1 agonist is influenced by a succession of factors including receptor reserve, phosphorylation, metabolism and uptake, CB1 receptor activation, voltage, temperature, pH and bovine serum albumin. There are indications that the endocannabinoid system may play a role in the modulation of TRPV1 receptor activation. The activation of TRPV1 receptors by anandamide has potential implications in the treatment of inflammatory, respiratory and cardiovascular disorders. The relative importance of anandamide as a physiological and/or pathophysiological TRPV1 receptor agonist in comparison to other potential candidates has yet to be revealed.

AB - A large body of evidence now exists to substantiate that the endocannabinoid, anandamide, activates TRPV1 receptors. It is a low intrinsic efficacy TRPV1 agonist that behaves as a partial agonist in tissues with a low receptor reserve, while in tissues with high receptor reserve and in circumstances associated with certain disease states, it behaves as a full agonist. The efficacy of anandamide as a TRPV1 agonist is influenced by a succession of factors including receptor reserve, phosphorylation, metabolism and uptake, CB1 receptor activation, voltage, temperature, pH and bovine serum albumin. There are indications that the endocannabinoid system may play a role in the modulation of TRPV1 receptor activation. The activation of TRPV1 receptors by anandamide has potential implications in the treatment of inflammatory, respiratory and cardiovascular disorders. The relative importance of anandamide as a physiological and/or pathophysiological TRPV1 receptor agonist in comparison to other potential candidates has yet to be revealed.

KW - anandamide

KW - vanilloid

KW - TRPV1

KW - cannabinoid

KW - endocannabinoid

KW - endovanilloid

KW - lipoxygenase

KW - PROTEIN-KINASE-C

KW - ACID AMIDE HYDROLASE

KW - CANNABINOID CB1 RECEPTOR

KW - PRIMARY SENSORY NEURONS

KW - NERVE GROWTH-FACTOR

KW - ROOT GANGLION NEURONS

KW - RAT SPINAL-CORD

KW - VR1 RECEPTORS

KW - PHARMACOLOGICAL CHARACTERIZATION

KW - FACILITATED TRANSPORT

U2 - 10.1038/sj.bjp.0705467

DO - 10.1038/sj.bjp.0705467

M3 - Article

VL - 140

SP - 790

EP - 801

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 5

ER -